Introduction
The preproghrelin gene encodes several peptides with different structure and function, acyl ghrelin, desacyl ghrelin and obestatin. Research during the past almost two decades has demonstrated, that the ghrelin system involves many interrelated peptides and receptors distributed in different tissues, forming a complex network, which exerts autocrine, paracrine and endocrine actions in order to tightly regulate different physiological and pathological processes.
Ghrelin is a 28 amino acid peptide and the endogenous ligand of the growth hormone secretagogue receptor 1a (GHS-R1a), originally identified from the rat stomach (Kojima et al.,1999) , as having orexigenic activity and regulating food intake, body weight and energy homeostasis. The normal ghrelin signaling is disturbed in eating disorders such as obesity, anorexia and bulimia nervosa. Later, ghrelin was also shown to have a crucial role in the integration of feeding signals with those regulating emotion and mood. Furthermore, it is involved in motivated and rewarding behaviours induced by food and different addictive substances (alcohol, cocaine, amphetamin). Considering the effects on anxiety and mood, multiple studies conducted in rodents have demonstrated that ghrelin can induce not only anxiety and depression-like behaviors but it also has anxiolytic-and anti-depressant-like effects. Accordingly, in unstressed animals the administration of ghrelin would favour anxiety-and depression-like behavior. The anxiolytic-and antidepressant-like effect of ghrelin on the other hand may be a critical counter-regulatory mechanism to cope with different stress conditions, promoting food seeking, maintanance of energy homeostasis and survival advantage during evolution. However, the activation of HPA axis and the release of glucocorticoids may enhance ghrelin's effect on the consumption of highly palatable, rewarding food both in animals and humans, but at the expense of high caloric intake and development of obesity.
Obestatin is a 23 amino-acid peptide, originally isolated from the rat stomach and identified as an anorexigenic hormone and antagonist of ghrelin (Zhang et al., 2005) .
However, obestatin is also expressed in other GI organs (pancreas, liver), adipose tissue, skeletal muscle, lungs, thyroid and mammary glands and testes, suggesting a multifunctional role of it, whith both central and peripheral effects. Later, most scientific papers refuted the anorexigenic effect of obestatin under a variety of conditions and only its acute food-intake inhibiting effect was reproducible. Despite these controversies, obestatin has been shown to antagonise acyl ghrelin's effect on growth hormone secretion and food intake in rodents and fish, while fasting resulted in elevated ghrelin-and reduced obestatin levels. Furthermore, in a variety of obesity syndromes with different etiology (monogenic obesity, metabolic syndrome, Prader-Willi syndrome), in anorexia-and bulimia nervosa, the values and the ratio of the preproghrelin products (total ghrelin, acyl ghrelin and obestatin) were found either reduced, unchanged or increased.
In the past years much of the scientific interest has focused on obestatin's effect on glucose metabolism, accordingly obestatin was identified as an important regulator of pancreatic endocrine function and antiapoptotic/ survival factor for pancreatic islet cells, promoting cell proliferation and insulin secretion. Obestatin levels are altered in patients with obesity, type 2 diabetes mellitus, insulin resistance and metabolic syndrome.
Obestatin can also modulate the function of adipose tissue, by promoting adipocyte differentiation and survival, and regulating lipogenesis/lipolysis and circulating lipid levels. Considering the crucial role of the adipose tissue dysregulation in obesity and diabetes, obestatin represents an attractive potential as a multitarget drug in these disorders.
Acting as a neuropeptide, it also exerts central effects, participating in the control and integration of neurocircuits which regulate metabolism, thirst, thermoregulation, and sleep. Additionally obestatin inhibits apoptosis and promotes proliferation and survival of hippocampal progenitor cells in vitro, which suggests a possible beneficial role in the treatment of neurodegenerative disorders. Obestatin also caused memory retention in two different tests (inhibitory avoidance and spontaneous object recognition), indicating that it influences both learning and memory processes related to brain structures such as the amygdala and hippocampus.
The aim of the study
 Until present, a single study has examined the effects of obestatin on anxiety in rats, indicating that it exerts anxiolytic-like effects in the elevated plus maze (EPM) test.
 In contrast to ghrelin, no data is available at present on obestatin's possible role in the behavioral responses related to depression or different drugs of addiction.  In order to underscore our behavioral results we also measured plasma corticosterone levels by fluorescence assay in the animal groups treated with obestatin and antalarmin.
 Furthermore, to find out whether obestatin's effect on anxiety and depression are mediated through Growth Hormone Secretagogue Receptor (GHSR) signaling, we administered ghrelin receptor antagonist pretreatment followed by OF testing and FST.
 Next, we investigated the possible effects of the chronic, central obestatin treatment on naloxone-precipitated morphine withdrawal, by using graded doses of morphine and obestatin, followed by testing the animals in the OF and EPM tests.
Materials and methods
Male CFLP mice (25-35 g body weight) of an outbred strain (Domaszék, Hungary) were used for the experiments in accordance with the rules of the Ethical Committee for the Protection of Animals in Research (Faculty of Medicine, University of Szeged, Hungary).
They were kept under a standard light-dark cycle (lights on between 07.00 and 19.00 h) with food and water available ad libitum. 
Treatment protocols

The effect of acute obestatin administration in the Open Field (OF) and EPM tests
The following behavioral parameters were detected in the OF (Conducta system, EXPERIMETRIA LTD. Hungary): ambulation distance and time, rearing, jumping, immobility time, as well as the percentage of distance and time spent in the center squares (center/total ambulation distance and time%). 
The effect of acute obestatin administration on plasma corticosterone levels
In order to determine plasma corticosterone concentrations, trunk blood was collected in heparinized tubes. The plasma corticosterone concentration was measured by fluorescence assay (described by Zenker and Bernstein as modified by Purves and Sirett).
Forced swimming test (FST)
In our laboratory the modified mouse FST was performed as described by Porsolt. During the test session the durations of swimming, climbing and immobility were registered for 5 min, with a time-sampling scoring technique (every 5 sec). The behavioral procedure and analysis was performed by using a video recording device and the FST files were transfered to a PC and analyzed by an independent observer.
5. Obestatin, morphine and the naloxone-precipitated withdrawal
Chronic morphine treatment was administered as described earlier. Mice received subcutaneous (sc), twice-daily injections of ascending doses of morphine (10-20-40 mg/kg), Mice were also treated daily with obestatin (1.5 μg/2 μl, aCSF icv). On the test day (day 4), a single dose of morphine (20 mg/kg,sc.) was given, followed by icv injection of obestatin. Withdrawal from morphine was achieved by the injection of 0.2 mg/kg of naloxone (naloxone-HCl, Sigma-Aldrich), followed by the testing of mice in the EPM or OF. Control mice received sc saline or icv aCSF.
Statistical analysis
Behavioral data were assessed by one-way ANOVA. Post-hoc individual means comparisons were conducted by Holm-Sidak method. Data with morphine treatment was analyzed by 2-way repeated measure. P< 0.05 was accepted as a significant statistical value.
Results
The effect of acute obestatin treatment in the OF and EPM tests
Acute central administration of obestatin had no effect on the overall locomotor activity, as 
The effect of obestatin treatment on plasma corticosterone levels
Plasma corticosterone levels were elevated by the different doses of obestatin, this effect has been reversed by the administration of antalarmin.
The effects of obestatin on naloxone -precipitated morfin withdrawal
EPM results
Treatment with the graded doses of morphine and obestatin did not influence significantly the total activity, OAT% and OAE%, respectively. Naloxone-precipitated withdrawal induced a significant increase in both OAT% and OAE%.
OF test results
Treatment with graded doses of morphine significantly decreased the percentage of center ambulation distance, while the percentage of time spent in the central area showed a decreasing tendency. Chronic administration of obestatin alone had no significant effect on the OF parameters. Naloxone-precipitated morphine withdrawal caused a significant increase in the percentage of central ambulation distance and time, the effect on central ambulation time was reversed by obestatin.
Results in the FST
Immobility score was significantly increased and the swimming score was decreased by obestatin. Pretreatment with antalarmin antagonized the effect of obestatin on both immobility and swimming score. Combined treatment with obestatin and the ghrelin receptor antagonist [D-Lys3]-GHRP6 decreased the immobility score, and increased both the swimming and the climbing scores.
Discussion
Obestatin exerts anxiogenic-and depressive-like effects via HPA axis and ghrelin receptor signaling
In our studies we demonstrated for the first time that obestatin exerts anxiogenic-like effects in mice in two different paradigms, namely the EPM and OF tests. It must be noted, however, that obestatin was originally reported to cause anxiolytic-like effects in rats in the EPM. A possible explanation for the contradictory results might be the differences in experimental design (dosage regimen, animal species/strains used) and conditions (basal vs. stressed), as well as feeding state (food available ad libitum vs. calorie restriction) which all have high impact on the outcome of behavioral studies related to both ghrelin and obestatin. In our studies obestatin was administered to unstressed mice, therefore, it is reasonable to assume that obestatin, similarly to ghrelin exerts anxiety-like action in basal conditions. Furthermore, in concert with our behavioral findings, the different doses of obestatin administered also elevated plasma corticosterone levels, which highlights the well-identified correlation between the HPA axis activation and anxiety-related conditions.
In our studies, administration of the CRHR1 antagonist antalarmin blunted the anxiogeniclike effect in the OF test and the elevation in plasma corticosterone levels induced by obestatin, suggesting the involvement of CRHR1 and HPA axis. In line with our findings, the anxiogenic-like effect of ghrelin was also suggested to be mediated by the stimulation of the HPA axis.
In our studies we demonstrated for the first time, that icv injection of obestatin, in a dose of 1 µg (which has also induced anxiety-like behavior in the EPM), significantly increased the immobility score, while decreasing the swimming score in the FST suggesting not only on anxiogenic-like, but also a depressive-like effect for obestatin. A possible explanation for the contradictory results related to the behavioral effects of naloxone-precipitated morphine withdrawal might be the differences in experimental design (dosage regimen, animal species/strains used).
It was also suggested, that EPM detects not only the anxiety behavior, but also several other aspects of emotionality and motivation, like neophobia (i.e. novelty-induced behavioral inhibition), exploration behavior, as well as defensive patterns to avoid and escape from withdrawal state.
Another possible explanation might be that delta and kappa opioid receptors, responsible for inducing and inhibiting anxiety, differentially adapt to the challenges of repeated morphine exposure and opioid withdrawal leading to diverse EPM behaviors in species.
In our studies obestatin treated mice undergoing withdrawal showed a decreasing tendency in open arm entries and open arm time in the EPM, and a significant decrease in central ambulation and time in the OF test.
The mechanism of action of obestatin on opiod withdrawal might involve the ERK1/2 signaling, which was recently identified to also mediate obestatin's beneficial effect on glucose metabolism and adipose tissue function.
Conclusions
In the past two decades an abundant number of extensive studies have focused to reveal the multiple functions of the brain-gut peptide ghrelin.
Identified originally as an orexigenic peptide, and an antagonist for ghrelin, in the past few years obestatin has also received growing attention. primarly due to its beneficial effects on glucose and lipid metabolism. However, the data related to obestatin's central effects are also continously extending, so far it has been proven to have a role in memory, learning, neuroprotection, thirst, sleep and thermoregulation. Our group has demonstrated for the first time that obestatin affects mood, anxiety and naloxone-precipitated morphine withdrawal in mice.
The exact underlying neurocircuits and the specific receptor for obestatin have not been discovered yet. However, the continously developing and more accurate experimental methods will hopefully identify obestatin as a diagnostic and therapeutical potential in different neuropsychiatric and metabolic disorders.
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